Multicenter study assessing the ability of clinical and molecular panel as predictive determinant of efficacy of regorafenib in metastatic colorectal cancer patients.

Trial Profile

Multicenter study assessing the ability of clinical and molecular panel as predictive determinant of efficacy of regorafenib in metastatic colorectal cancer patients.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms REINVENT
  • Most Recent Events

    • 07 Dec 2016 New trial record
    • 11 Oct 2016 Trial design presented at 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top